দেশ: মাল্টা
ভাষা: ইংরেজি
সূত্র: Medicines Authority
PAZOPANIB
PharOS – Pharmaceutical Oriented Services Limited Lesvou str. (end), Thesi Loggos, Industrial Zone, 144 52 Metamorfossi Attikis,, Greece
L01EX03
PAZOPANIB 400 mg
FILM-COATED TABLET
PAZOPANIB 400 mg
POM
ANTINEOPLASTIC AGENTS
Licence number in the source country: NOT APPLICAPABLE
Authorised
2022-01-03
Page 1 of 10 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT PAZOPANIB PHAROS 200 MG FILM-COATED TABLETS PAZOPANIB PHAROS 400 MG FILM-COATED TABLETS pazopanib READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Pazopanib PharOS is and what it is used for 2. What you need to know before you take Pazopanib PharOS 3. How to take Pazopanib PharOS 4. Possible side effects 5. How to store Pazopanib PharOS 6. Contents of the pack and other information 1. WHAT PAZOPANIB PHAROS IS AND WHAT IT IS USED FOR Pazopanib PharOS is a type of medicine called a _protein kinase inhibitor. _ It works by preventing the activity of proteins that are involved in the growth and spread of cancer cells. Pazopanib PharOS is used in adults to treat: - kidney cancer that is advanced or has spread to other organs. - certain forms of soft-tissue sarcoma, which is a type of cancer that affects the supportive tissues of the body. It can occur in muscles, blood vessels, fat tissue or other tissues that support, surround and protect the organs. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE PAZOPANIB PHAROS DO NOT TAKE PAZOPANIB PHAROS - IF YOU ARE ALLERGIC to pazopanib or any of the other ingredients of this medicine (listed in section 6). CHECK WITH YOUR DOCTOR if you think this applies to you. WARNINGS AND PRECAUTIONS Talk to your doctor before taking Pazopanib PharOS: - if you have HEART DISEASE. - if you have LIVER DISEASE. - if you have had HEART FAILURE OR A HEART ATTACK. - if you have had prior COLLAPSE OF A LUNG. - if you have had pro সম্পূর্ণ নথি পড়ুন
Page 1 of 31 _Pazopanib PharOS 400 mg film-coated tablets: _ Each tablet contains pazopanib hydrochloride equivalent to 400 mg pazopanib _Pazopanib PharOS 400 mg film-coated tablets: _ Capsule-shaped, white, film-coated tablet with “400” debossed on one side, with dimensions 18.0 mm x 7.1 mm approximately. SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Pazopanib PharOS 200 mg film-coated tablets Pazopanib PharOS 400 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION _Pazopanib PharOS 200 mg film-coated tablets: _ Each tablet contains pazopanib hydrochloride equivalent to 200 mg pazopanib For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). _Pazopanib PharOS 200 mg film-coated tablets: _ Capsule-shaped, pink, film-coated tablet with “200” debossed on one side, with dimensions 14.3 mm x 5.7 mm approximately. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Renal cell carcinoma (RCC) Pazopanib PharOS is indicated in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Soft-tissue sarcoma (STS) Pazopanib PharOS is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. Efficacy and safety has only been established in certain STS histological tumour subtypes (see section 5.1). Page 2 of 31 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Pazopanib PharOS treatment should only be initiated by a physician experienced in the administration of anti-cancer medicinal products. Posology _Adults _ The recommended dose of pazopanib for the treatment of RCC or STS is 800 mg once daily. _Dose modifications _ Dose modification (decrease or increase) should be in 200 mg decrements or increments in a stepwise fashion based on individual tolerability in order to man সম্পূর্ণ নথি পড়ুন